BioRestorative Therapies, Inc. ("BRT" or the "Company")
(OTCBB:BRTX), a life sciences company focused on adult stem
cell-based products and therapies for various personal medical
applications, today announced the appointment of Charles S. Ryan, J.D.,
Ph.D. to its Board of Directors.
Dr. Ryan is an experienced senior executive with an impressive
background in working in the pharmaceutical and biotechnology industry.
Currently, he is the Vice President, General Counsel for Cold Spring
Harbor Laboratory, a preeminent international research institution in
New York. Prior to this position, Dr. Ryan served for over a decade at
Forest Laboratories, a specialty pharmaceutical company in New York, as
its Senior Vice President & Chief Intellectual Property Counsel. Forest
Laboratories was acquired by Actavis in July 2014 for $28 billion.
Dr. Ryan possesses management and technical skills with regard to
various areas, including the implementation of strategic plans and
business development, intellectual property, mergers and acquisitions,
and research and business development. He has led hundreds of due
diligence investigation teams comprised of experts in areas relating to
research and development, clinical, pre-clinical, regulatory,
toxicology, commercial and intellectual property matters in connection
with business acquisitions.
“With a career spanning more than 16 years in the public company sector,
Dr. Ryan brings significant value and extraordinary skills to BRT with
regard to capital acquisition, due diligence and transaction activities
and patent and trademark preparation and prosecution,” said BRT CEO,
Mark Weinreb. “We are pleased to welcome Dr. Ryan and to strengthen our
Company by adding another accomplished and experienced member to our
Board. As we move forward, we are pleased to have the value of his
knowledge and expertise to help guide the Company into our next stage of
development.”
Dr. Ryan serves on the Boards of other public, private and non-profit
companies, including Applied DNA Sciences, Inc., ABS Materials, Inc.,
GlycoMira Therapeutics, the Center for Biotechnology Advisory Board, and
The College of Wooster Board of Trustees. He earned his B.A. in
Chemistry from The College of Wooster in 1986, a Ph.D. in Oral Biology
and Pathology from Stony Brook University in 1990 and his J.D. from
Western New England University in 1993.
Dr. Ryan is filling the vacancy on the Board created by the resignation
of Joseph Swiader, who stepped down due to other business commitments.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com)
develops products and medical therapies using cell and tissue protocols,
primarily involving adult stem cells, including:
-
Disc/Spine Program: Our lead cell therapy
candidate, brtxDISC™ (Disc Implanted Stem
Cells), is a product formulated from autologous (or a person’s
own) cultured mesenchymal stem cells collected from the patient’s bone
marrow. We intend that the product will be used for the non-surgical
treatment of protruding and bulging lumbar discs in patients suffering
from chronic lumbar disc disease. The treatment involves
collecting a patient’s own stem cells, culturing and cryopreserving
the cells, and then having a physician inject brtxDISC™
into the patient’s damaged disc in an outpatient procedure. The
treatment is intended for patients whose pain has not been alleviated
by non-invasive procedures and who potentially face the prospect of
surgery.
-
ThermoStem® Program: We
are developing an allogeneic cell-based therapy to target obesity and
metabolic disorders using brown adipose (fat) derived stem cells to
generate brown adipose tissue (“BAT”). BAT is intended to mimic
naturally occurring brown adipose depots that regulate metabolic
homeostasis in humans. Initial preclinical research indicates that
increased amounts of brown fat in the body may be responsible for
additional caloric burning as well as reduced glucose and lipid
levels. Researchers have found that people with higher levels of brown
fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You
are cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the forward-looking
statements as a result of various factors and other risks, including
those set forth in the Company's Form 10-K filed with the Securities and
Exchange Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance
on such statements. The forward-looking statements in this release are
made as of the date hereof and the Company undertakes no obligation to
update such statements.
Copyright Business Wire 2015